Literature DB >> 35909252

Anti-SARS-CoV-2 vaccination, safety and disease exacerbation in Behçet's syndrome: Correspondence.

Pathum Sookaromdee1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2022        PMID: 35909252      PMCID: PMC9353422          DOI: 10.1111/1756-185X.14410

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.558


× No keyword cloud information.
Dear Editor, we would like to share ideas on “Effects of anti‐SARS‐CoV‐2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort”. According to Apaydin et al, COVID‐19 vaccines are well tolerated by Behçet's syndrome patients, whereas more side effects appear following messenger RNA vaccines. Regardless of the vaccine type, exacerbations following the COVID‐19 vaccine are frequent, primarily involving the mucosa and joints, while exacerbations involving other organs are uncommon. We both agree there may be a connection between the COVID‐19 infection and the vaccine. Even while the COVID‐19 vaccination is beneficial, we are all concerned that it might also be dangerous. It is impossible to tell what led to the hematologic issue in this case because there was insufficient pre‐vaccination information on the health and immunological status of vaccine recipients. Due to conflicting facts, people may grow discouraged and oppose immunizations. Patient comorbidity may be the cause of the issue. It was evident that the patient had a clinical illness, but this did not mean there were no other co‐morbid diseases. A group of people with known pre‐vaccination immunological and health statuses who were afterward followed to assess how the vaccine affected the disease would provide more conclusive evidence on this topic.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST

None.
  2 in total

1.  Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Behçet syndrome in a monocentric cohort.

Authors:  Hakan Apaydin; Abdulsamet Erden; Serdar Can Güven; Berkan Armağan; Hatice Ecem Konak; Bünyamin Polat; Yağnur Afşin; Merve Kaygisiz; Ahmet Omma; Orhan Kucuksahin
Journal:  Int J Rheum Dis       Date:  2022-07-18       Impact factor: 2.558

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.